Connection
Search Results to J. Steven Leeder
This is a "connection" page, showing the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of
Leeder, J. Steven
Property | Value |
keywords
|
Pediatric Clinical Pharmacology
|
keywords
|
Pediatric Pharmacogenetics
|
keywords
|
Pediatric Precision Therapeutics
|
research overview
|
In his former role as Director of the Division of Clinical Pharmacology and Therapeutic Innovation at Children’s Mercy Dr. Leeder led a program consisting of multidisciplinary teams of researchers with expertise in analytical chemistry, drug biotransformation, gene regulation, pharmacogenomics, and pharmacokinetics to investigate variability in medication response in children. An important component of the program was to provide an environment in which trainees and early career faculty members from diverse backgrounds could develop as independent investigators in their areas of research interest. These research interests generally are closely aligned with their clinical expertise with the goal of implementing precision therapeutics in their clinical subspecialties to benefit the patients they serve.
Currently, Dr Leeder is Executive Director (Interim) of the Children’s Mercy Research Institute and leads the Precision Therapeutics Area of Emphasis. The Precision Therapeutics initiative extends the Division of Clinical Pharmacology's emphasis on developing individuals to a more institutional level by providing support to pediatric subspecialties interested in adding precision therapeutics to their portfolio of research programs. In this way the program serves as a model of integrated research that will extend throughout the CMRI.
Over the years, Dr. Leeder's research interests in pediatric pharmacogenetics and the ontogeny of drug biotransformation pathways during growth and development have coalesced into the GOLDILOKs initiative: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids. Originally funded as one of four Specialized Centers for Research in Pediatric Developmental Pharmacology supported by the Eunice Kennedy Shriver National Institute for Child Health and Human Development, "GOLDILOKs" now represents a conceptual approach to better understanding factors contributing to variability in drug disposition and response and using that information to make the use of medications safer and more effective in children of all ages.
Dr. Leeder is also co-PI, with Dr. Mario Castro (KUMC), of the Frontiers Clinical and Translational Science Institute at the University of Kansas.
|
One or more keywords matched the following items that are connected to
Leeder, J. Steven
Item Type | Name |
Concept
|
Hospitals, Pediatric
|
Concept
|
Pediatrics
|
Concept
|
Intensive Care Units, Pediatric
|
Concept
|
Pediatric Obesity
|
Academic Article
|
Pharmacogenetics and pharmacogenomics.
|
Academic Article
|
The challenges of delivering pharmacogenomics into clinical pediatrics.
|
Academic Article
|
Developmental and pediatric pharmacogenomics.
|
Academic Article
|
Developmental pharmacology--drug disposition, action, and therapy in infants and children.
|
Academic Article
|
Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond.
|
Academic Article
|
Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression.
|
Academic Article
|
Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.
|
Academic Article
|
Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.
|
Academic Article
|
Conference scene: pediatric pharmacogenomics and personalized medicine.
|
Academic Article
|
Development of biomarkers to optimize pediatric patient management: what makes children different?
|
Academic Article
|
Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.
|
Academic Article
|
Trends in adverse reactions to trimethoprim-sulfamethoxazole.
|
Academic Article
|
Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control.
|
Academic Article
|
Pharmacogenetics in pediatrics. Implications for practice.
|
Academic Article
|
Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.
|
Academic Article
|
Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.
|
Academic Article
|
Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers.
|
Academic Article
|
Quantification of pravastatin acid, lactone and isomers in human plasma by UHPLC-MS/MS and its application to a pediatric pharmacokinetic study.
|
Academic Article
|
Cost and Potential Avoidability of Antibiotic-Associated Adverse Drug Reactions in Children.
|
Academic Article
|
Ontogeny-related pharmacogene changes in the pediatric liver transcriptome.
|
Academic Article
|
Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.
|
Academic Article
|
Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.
|
Academic Article
|
Newborn Sequencing in Genomic Medicine and Public Health.
|
Academic Article
|
Pediatric Pharmacovigilance: Enhancing Adverse Drug Reaction Reporting in a Tertiary Care Children's Hospital.
|
Academic Article
|
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.
|
Academic Article
|
Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia.
|
Academic Article
|
Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
|
Academic Article
|
Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy
|
Academic Article
|
In: Problems in Pediatric Drug Therapy, Fourth Edition, Pagliaro LA and Pagliaro AM (Eds)
|
Academic Article
|
In: Neonatal and Pediatric Pharmacology, Third Edition, Yaffe S and Aranda J, (Eds)
|
Academic Article
|
In: Nelson Textbook of Pediatrics, 18th Edition, Kliegman, Behrman, Jenson and Stanton, (Eds)
|
Academic Article
|
In: Neonatal and Pediatric Pharmacology, Fourth Edition, Yaffe S and Aranda J, (Eds
|
Academic Article
|
In: Nelson Textbook of Pediatrics, 19th Edition, Kliegman RM, Stanton BF, St. Geme III JW, Schor NF, Behrman RE, (Eds)
|
Academic Article
|
Principles of Drug Administration in Children Receiving Renal Replacement Therapy Second Edition
|
Academic Article
|
In Biochemical and Molecular Basis of Pediatric Disease, 4th Ed., Wong E, Bennett M, and Dietzen D, eds
|
Academic Article
|
In: Principles of Pharmacogenetics and Pharmacogenomics, Altman RB, Flockhart D, and Goldstein DB, (Eds),
|
Academic Article
|
In: Nelson Textbook of Pediatrics, 20th Edition, Kliegman RM, Stanton BF, St. Geme III JW, Schor NF, (Eds)
|
Academic Article
|
In: Textbook of Pediatric Rheumatology, Seventh Edition, Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, (Eds)
|
Academic Article
|
Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy.
|
Academic Article
|
Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver.
|
Academic Article
|
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.
|
Award or Honor Receipt
|
Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics
|
Academic Article
|
Ontogeny Related Changes in the Pediatric Liver Metabolome.
|
Academic Article
|
Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver.
|
Academic Article
|
Ontogeny of Pediatric Pharmacogenetics: Celebrating the Past and Vision for the Future.
|
Academic Article
|
Pediatric growth patterns in youth-onset type 2 diabetes mellitus: Implications for physiologically-based pharmacokinetic models.
|
Academic Article
|
Genomic answers for children: Dynamic analyses of >1000 pediatric rare disease genomes.
|
Grant
|
Ontogeny of drug transport
|
Grant
|
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
|
Grant
|
Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology
|
Grant
|
Effect of Obesity on Pantoprazole Pharmacokinetics and Pharmacodynamics in Children
|
Academic Article
|
Ontogeny of Scaling Factors for Pediatric Physiologically Based Pharmacokinetic Modeling and Simulation: Cytosolic Protein Per Gram of Liver.
|
Academic Article
|
SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia.
|
Academic Article
|
Age-Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling.
|
|
|